PMC:7461420 / 731-950 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T5","span":{"begin":6,"end":16},"obj":"Disease"},{"id":"T6","span":{"begin":143,"end":147},"obj":"Disease"},{"id":"T7","span":{"begin":165,"end":169},"obj":"Disease"}],"attributes":[{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"t CoV infections are available. In this review, we focus on the medicinal chemistry efforts toward the development of antiviral agents against SARS‐CoV‐1, MERS‐CoV, SARS‐CoV‐2, targeting biochemical events important for"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T66400","span":{"begin":51,"end":56},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"t CoV infections are available. In this review, we focus on the medicinal chemistry efforts toward the development of antiviral agents against SARS‐CoV‐1, MERS‐CoV, SARS‐CoV‐2, targeting biochemical events important for"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T2","span":{"begin":118,"end":134},"obj":"Chemical"}],"attributes":[{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"t CoV infections are available. In this review, we focus on the medicinal chemistry efforts toward the development of antiviral agents against SARS‐CoV‐1, MERS‐CoV, SARS‐CoV‐2, targeting biochemical events important for"}

{"project":"LitCovid-PubTator","denotations":[{"id":"40","span":{"begin":2,"end":5},"obj":"Species"},{"id":"41","span":{"begin":143,"end":151},"obj":"Species"},{"id":"42","span":{"begin":155,"end":163},"obj":"Species"},{"id":"43","span":{"begin":165,"end":175},"obj":"Species"},{"id":"47","span":{"begin":6,"end":16},"obj":"Disease"}],"attributes":[{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:11118"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Tax:694009"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"Tax:1335626"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"Tax:2697049"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"t CoV infections are available. In this review, we focus on the medicinal chemistry efforts toward the development of antiviral agents against SARS‐CoV‐1, MERS‐CoV, SARS‐CoV‐2, targeting biochemical events important for"}